[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

COVID-19 Recombinant Protein Vaccine Market - Global Outlook and Forecast 2021-2027

April 2021 | 90 pages | ID: CA7683E41204EN
Market Monitor Global

US$ 3,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report contains market size and forecasts of COVID-19 Recombinant Protein Vaccine in Global, including the following market information:

Global COVID-19 Recombinant Protein Vaccine Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global COVID-19 Recombinant Protein Vaccine market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the COVID-19 Recombinant Protein Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global COVID-19 Recombinant Protein Vaccine Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global COVID-19 Recombinant Protein Vaccine Market Segment Percentages, By Type, 2020 (%)
  • Being Developed
  • Preclinical
  • Clinical I
  • Clinical II
China COVID-19 Recombinant Protein Vaccine Market, By Application, 2016-2021, 2022-2027 ($ millions)

China COVID-19 Recombinant Protein Vaccine Market Segment Percentages, By Application, 2020 (%)
  • Pharmaceutical And Biotechnology Companies
  • Hospital
  • Academic And Research Organizations
  • Other
Global COVID-19 Recombinant Protein Vaccine Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global COVID-19 Recombinant Protein Vaccine Market Segment Percentages, By Region and Country, 2020 (%)
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Benelux
    • Rest of Europe
  • Asia
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Rest of Asia
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • Turkey
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa
Competitor Analysis

The report also provides analysis of leading market participants including:

Total COVID-19 Recombinant Protein Vaccine Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total COVID-19 Recombinant Protein Vaccine Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:
  • GSK
  • Johnson & Johnson
  • Sanofi
  • Novavax
  • Pukang Biologic Technology
  • Clover Biopharmaceuticals
  • Suzhou Yuzhibo Biotechnology
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 COVID-19 Recombinant Protein Vaccine Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global COVID-19 Recombinant Protein Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL COVID-19 RECOMBINANT PROTEIN VACCINE OVERALL MARKET SIZE

2.1 Global COVID-19 Recombinant Protein Vaccine Market Size: 2021 VS 2027
2.2 Global COVID-19 Recombinant Protein Vaccine Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top COVID-19 Recombinant Protein Vaccine Players in Global Market
3.2 Top Global COVID-19 Recombinant Protein Vaccine Companies Ranked by Revenue
3.3 Global COVID-19 Recombinant Protein Vaccine Revenue by Companies
3.4 Top 3 and Top 5 COVID-19 Recombinant Protein Vaccine Companies in Global Market, by Revenue in 2020
3.5 Global Companies COVID-19 Recombinant Protein Vaccine Product Type
3.6 Tier 1, Tier 2 and Tier 3 COVID-19 Recombinant Protein Vaccine Players in Global Market
  3.6.1 List of Global Tier 1 COVID-19 Recombinant Protein Vaccine Companies
  3.6.2 List of Global Tier 2 and Tier 3 COVID-19 Recombinant Protein Vaccine Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global COVID-19 Recombinant Protein Vaccine Market Size Markets, 2021 & 2027
  4.1.2 Being Developed
  4.1.3 Preclinical
  4.1.4 Clinical I
  4.1.5 Clinical II
4.2 By Type - Global COVID-19 Recombinant Protein Vaccine Revenue & Forecasts
  4.2.1 By Type - Global COVID-19 Recombinant Protein Vaccine Revenue, 2016-2021
  4.2.2 By Type - Global COVID-19 Recombinant Protein Vaccine Revenue, 2022-2027
  4.2.3 By Type - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global COVID-19 Recombinant Protein Vaccine Market Size, 2021 & 2027
  5.1.2 Pharmaceutical And Biotechnology Companies
  5.1.3 Hospital
  5.1.4 Academic And Research Organizations
  5.1.5 Other
5.2 By Application - Global COVID-19 Recombinant Protein Vaccine Revenue & Forecasts
  5.2.1 By Application - Global COVID-19 Recombinant Protein Vaccine Revenue, 2016-2021
  5.2.2 By Application - Global COVID-19 Recombinant Protein Vaccine Revenue, 2022-2027
  5.2.3 By Application - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global COVID-19 Recombinant Protein Vaccine Market Size, 2021 & 2027
6.2 By Region - Global COVID-19 Recombinant Protein Vaccine Revenue & Forecasts
  6.2.1 By Region - Global COVID-19 Recombinant Protein Vaccine Revenue, 2016-2021
  6.2.2 By Region - Global COVID-19 Recombinant Protein Vaccine Revenue, 2022-2027
  6.2.3 By Region - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027
  6.3.2 US COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.3.3 Canada COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.3.4 Mexico COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027
  6.4.2 Germany COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.3 France COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.4 U.K. COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.5 Italy COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.6 Russia COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.7 Nordic Countries COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.4.8 Benelux COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027
  6.5.2 China COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.5.3 Japan COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.5.4 South Korea COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.5.5 Southeast Asia COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.5.6 India COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027
  6.6.2 Brazil COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.6.3 Argentina COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027
  6.7.2 Turkey COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.7.3 Israel COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.7.4 Saudi Arabia COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027
  6.7.5 UAE COVID-19 Recombinant Protein Vaccine Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 GSK
  7.1.1 GSK Corporate Summary
  7.1.2 GSK Business Overview
  7.1.3 GSK COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.1.4 GSK COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.1.5 GSK Key News
7.2 Johnson & Johnson
  7.2.1 Johnson & Johnson Corporate Summary
  7.2.2 Johnson & Johnson Business Overview
  7.2.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.2.4 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.2.5 Johnson & Johnson Key News
7.3 Sanofi
  7.3.1 Sanofi Corporate Summary
  7.3.2 Sanofi Business Overview
  7.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.3.4 Sanofi COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.3.5 Sanofi Key News
7.4 Novavax
  7.4.1 Novavax Corporate Summary
  7.4.2 Novavax Business Overview
  7.4.3 Novavax COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.4.4 Novavax COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.4.5 Novavax Key News
7.5 Pukang Biologic Technology
  7.5.1 Pukang Biologic Technology Corporate Summary
  7.5.2 Pukang Biologic Technology Business Overview
  7.5.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.5.4 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.5.5 Pukang Biologic Technology Key News
7.6 Clover Biopharmaceuticals
  7.6.1 Clover Biopharmaceuticals Corporate Summary
  7.6.2 Clover Biopharmaceuticals Business Overview
  7.6.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.6.4 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.6.5 Clover Biopharmaceuticals Key News
7.7 Suzhou Yuzhibo Biotechnology
  7.7.1 Suzhou Yuzhibo Biotechnology Corporate Summary
  7.7.2 Suzhou Yuzhibo Biotechnology Business Overview
  7.7.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Major Product Offerings
  7.4.4 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Revenue in Global (2016-2021)
  7.7.5 Suzhou Yuzhibo Biotechnology Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES

Table 1. COVID-19 Recombinant Protein Vaccine Market Opportunities & Trends in Global Market
Table 2. COVID-19 Recombinant Protein Vaccine Market Drivers in Global Market
Table 3. COVID-19 Recombinant Protein Vaccine Market Restraints in Global Market
Table 4. Key Players of COVID-19 Recombinant Protein Vaccine in Global Market
Table 5. Top COVID-19 Recombinant Protein Vaccine Players in Global Market, Ranking by Revenue (2019)
Table 6. Global COVID-19 Recombinant Protein Vaccine Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global COVID-19 Recombinant Protein Vaccine Revenue Share by Companies, 2016-2021
Table 8. Global Companies COVID-19 Recombinant Protein Vaccine Product Type
Table 9. List of Global Tier 1 COVID-19 Recombinant Protein Vaccine Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 COVID-19 Recombinant Protein Vaccine Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - COVID-19 Recombinant Protein Vaccine Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - COVID-19 Recombinant Protein Vaccine Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - COVID-19 Recombinant Protein Vaccine Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - COVID-19 Recombinant Protein Vaccine Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2022-2027
Table 30. GSK Corporate Summary
Table 31. GSK COVID-19 Recombinant Protein Vaccine Product Offerings
Table 32. GSK COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product Offerings
Table 35. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 36. Sanofi Corporate Summary
Table 37. Sanofi COVID-19 Recombinant Protein Vaccine Product Offerings
Table 38. Sanofi COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 39. Novavax Corporate Summary
Table 40. Novavax COVID-19 Recombinant Protein Vaccine Product Offerings
Table 41. Novavax COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 42. Pukang Biologic Technology Corporate Summary
Table 43. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product Offerings
Table 44. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 45. Clover Biopharmaceuticals Corporate Summary
Table 46. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product Offerings
Table 47. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)
Table 48. Suzhou Yuzhibo Biotechnology Corporate Summary
Table 49. Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product Offerings
Table 50. Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Revenue (US$, Mn), (2016-2021)

LIST OF FIGURES

Figure 1. COVID-19 Recombinant Protein Vaccine Segment by Type
Figure 2. COVID-19 Recombinant Protein Vaccine Segment by Application
Figure 3. Global COVID-19 Recombinant Protein Vaccine Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global COVID-19 Recombinant Protein Vaccine Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global COVID-19 Recombinant Protein Vaccine Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by COVID-19 Recombinant Protein Vaccine Revenue in 2020
Figure 8. By Type - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 9. By Application - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 10. By Region - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 11. By Country - North America COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 12. US COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 13. Canada COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 16. Germany COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 17. France COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 19. Italy COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 20. Russia COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 24. China COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 25. Japan COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 28. India COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 30. Brazil COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2016-2027
Figure 33. Turkey COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 34. Israel COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 36. UAE COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2016-2027
Figure 37. GSK COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Sanofi COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Novavax COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)


More Publications